INTRODUCTION
Ceftaroline fosamil (ceftaroline hereafter) is the latest addition to the armamentarium for the treatment of patients with community-acquired pneumonia (CAP), including those with a documented bacterial pneumonia. It is currently approved by the FDA for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Grampositive and Gram-negative microorganisms:
Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only),
Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli [1] . The purpose of this review is to summarize the major efficacy and effectiveness findings of ceftaroline from the Phase III CAP clinical trials [2] [3] [4] and from the ''Ceftaroline Assessment Program and Teflaro Ò Utilization
Registry'' (CAPTURE) [5] [6] [7] [8] [9] [10] .
When reviewing the Phase III ''efficacy'' and post-marketing ''effectiveness'' data for ceftaroline, it is important to appreciate the distinction between CAP and CABP [11, 12] .
Both CAP and CABP are acute infections of the lower respiratory tract (pulmonary parenchyma) among patients not hospitalized or residing in a long-term care facility for C14 days before the onset of symptoms [11] [12] [13] [14] . The difference between CAP and CABP lies in their etiology.
Community-acquired pneumonia can be caused by bacterial pathogens and certain respiratory viruses. Its etiology is often unknown at clinical presentation [13, 14] . In contrast, CABP is the recent Food and Drug Administration (FDA) designation to identify individuals with a documented bacterial pneumonia [11, 12] . The FDA decided to make this distinction to more appropriately identify patients who are most likely to have pneumonia of bacterial etiology and who would benefit most from antimicrobial therapy [15, 16] . This is a critical distinction, since the etiology of CAP is often unknown in both clinical trials and clinical practice [2-4, 13, 14, 17] . In clinical trials, bacterial pathogens are identified in only 25% of cases [2, 4, 17] . In practice, a microbiological diagnosis in CAP occurs in less than 10% of cases [18] . Thus, although it is approved by the FDA for CABP, much of its use in the real-world setting is for CAP since the bacterial etiology is not frequently established [18] . As such, it is important to understand the efficacy and effectiveness of ceftaroline in these two distinct yet related disease states when evaluating its potential for use in clinical practice.
METHODS
Studies included were the CAP FOCUS trials (NCT00621504 and NCT00509106) and studies evaluating effectiveness of ceftaroline in the treatment of CAP and CABP from the CAPTURE registry.
Compliance with Ethics
The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. As mentioned above, the FDA updated its guidance as ceftaroline was proceeding through the regulatory process [12, 20] . Rather than focusing on CAP and TOC assessments for evaluating clinical response and determining non-inferiority, the FDA endorsed the use of an early clinical response endpoint between study days 3-5 based on clinical symptom improvement and stabilization of vital signs among patients with a documented CABP.
CEFTAROLINE
Given the change in guidance, a post hoc analysis of day 4 response rates was performed among patients enrolled in the FOCUS studies who met the following inclusion criteria:
received at least one dose of study drug, had CAP that met radiographic criteria, had at least one symptom at baseline, and had one or more acceptable baseline typical pathogens [21] . This change in endpoint is clinically relevant because clinicians are unlikely to wait until the end of therapy to assess clinical response in practice. Rather, clinicians' early assessment of clinical response is more likely to guide therapy and subsequent therapy changes. Hence, the updated trial design improved the external validity of the clinical findings. The early response endpoint is also consistent with the definition of a patient eligible for hospital discharge in the ATS/IDSA CAP guidelines [14] .
In the combined analysis of FOCUS 1 and FOCUS 2, response rates at day 4 were 69.5% for ceftaroline and 59.4% for ceftriaxone (difference 10.1%, 95% CI, -0.6% to 20.6%). Among patients infected with S. pneumoniae, day 4 response rates were statistically significantly higher with ceftaroline (73%, 54/74) relative to ceftriaxone (56%, 42/75) (difference 17%, 95% CI, 1.4-31.6%; p = 0.03).
The response rates at day 4 for patients with MSSA were 58.3% (14/24) for those treated with ceftaroline and 54.8% (17/31) for ceftriaxone (difference 3.5%, 95% CI, -24.7% to 26.2%) [21] .
Interpretation of Findings from Phase III Studies
Collectively, these findings suggest that, with regard to efficacy, ceftaroline is a non-inferior alternative to ceftriaxone for the treatment of PORT III and IV hospitalized patient with CABP. The study findings also indicate that ceftaroline has utility in the empiric treatment of noncritically hospitalized patients with CAP. The comparative data were highly notable for patients with culture-confirmed S. pneumoniae, the most common cause of CABP. The more favorable early response at day 4 with ceftaroline among those with cultureconfirmed S. pneumoniae is suggestive of a more accelerated time to clinical stability, and hence, hospital discharge. Although the definitive reason in response rates at day 4 and TOC among patients with culture-confirmed S.
pneumoniae are unclear, the differences in outcomes may be explained by ceftaroline's enhanced affinity for penicillin-binding protein (PBP) 1a, 2a, 2b, and 2x as compared to ceftriaxone [22] . Despite the positive findings, the FOCUS trials were not without limitations. Specifically, critically ill patients in the ICU, those with culture-confirmed MRSA pneumonia, and those with severe renal dysfunction were excluded. These patients are important special populations because they may more accurately describe the patient population who may benefit from treatment with ceftaroline.
Consequently, it is vital to examine the realworld effectiveness of any new antibiotic as it is used in a broader range of patients among patients with both CAP and CABP.
Experience with Ceftaroline in the CAPTURE Registry
CAPTURE is a multicenter, retrospective registry of patients receiving ceftaroline dosed per package insert recommendations (i.e., 600 mg intravenously twice a day or dose adjusted for renal dysfunction) for the treatment of CABP and CAP. The data generated from CAPTURE provide critical insights into the real-world effectiveness of ceftaroline for both CABP and CAP [5] [6] [7] [8] [9] [10] . It provides clinical outcome data on patient populations and bacterial pathogens not well represented or excluded in the Phase III clinical trials (i.e., MRSA). The CAPTURE program also provides the opportunity to collect data on outcomes not traditionally examined in Phase III trials, like hospital length of stay and healthcare costs. .7) days. Most patients were discharged to home (58%) or another healthcare facility (38%).
Patients seldom discontinued treatment due to adverse events (n = 6, 2%). These findings suggest that in a real-world setting, ceftaroline has similar effectiveness as compared to that observed in the Phase III clinical trials.
Several caveats should be noted when interpreting these findings. First, 84% of patients received antibiotics prior to ceftaroline. The most commonly used antibiotics were other cephalosporins (35%), glycopeptides (34%), quinolones (32%), macrolides (25%), and penicillins (21%).
However, the authors note that clinical success was similar in patients receiving prior antibiotics as compared to those without prior antibiotics (77% and 75%, respectively). In addition, it is important to recognize that less than one-half of patients received ceftaroline as monotherapy (37%). Patients that received combinations of ceftaroline often received quinolones (21%), macrolides (20%), and glycopeptides (13%). Concurrent utilization of additional antibiotics may lead to overestimation of the treatment effect of ceftaroline. Lastly, the failure to note differences within subgroups may be due to limited power. These data suggest that there may be a cost benefit from utilizing ceftaroline as first-line therapy. Overall, those who received ceftaroline as first-line therapy tended to have shorter lengths of stays and lower total hospital charges. However, there are several important considerations with these data. The findings were descriptive in nature and multivariate statistics were not performed. Therefore, it is unclear if unequal distribution of baseline characteristics or unmeasured confounders may have affected the study results. In the patients receiving ceftaroline as non-first line therapy it is possible that these patients were switched from inactive or insufficient therapy.
These delays in time to appropriate therapy may account for some of the observed differences between study groups. Hence, prior to adopting ceftaroline as a first-line therapy for the purpose of cost savings, additional research is needed.
Special Populations Within CAPTURE
In addition to validating findings from the FOCUS trials, CAPTURE also examined outcomes in previously unexamined special populations. In FOCUS, critically ill patients in intensive care units were excluded [24] .
However, critically ill patients were eligible for enrollment in CAPTURE. In the first CAPTURE evaluation of patients with CAP, 99 (36%) patients were admitted to the ICU and their cure rate was 67%. These data suggest that there may be a role for ceftaroline in treatment of CAP among patients admitted to the ICU.
The CAPTURE registry also provided a unique opportunity to examine ceftaroline use with and without vancomycin for patients with CAP [24] . For this analysis, data were available on 175 patients with CAP. Among these patients, 77% (n = 134) received ceftaroline monotherapy and 23% (n = 41) received ceftaroline plus vancomycin. Baseline demographics were similar to previous CAPTURE evaluations. Patients receiving ceftaroline monotherapy and combination therapy had a similar average (median) LOT (6.4 [6] vs 6.8 (6) days, respectively, p-value not reported). The mean total hospital length of stay was longer in the combination group (20.9 vs. 14.6 days, p-value not reported). Numerically similar proportions of patients receiving monotherapy and combination therapy were discharged to home (55% vs. 41%, p-value not reported) or another care facility (40% vs. 44%, p-value not reported).
Four patients expired in the study period, all of which were in the combination group.
Although these data may suggest that the addition of vancomycin to ceftaroline for CAP does not improve outcomes, it is important to note that more patients in the combination therapy group were admitted to the ICU.
Conversely, ceftaroline monotherapy was more common in the general practice units (66%). This potential selection bias may have skewed the results in favor of ceftaroline monotherapy but more data are needed in each patient care setting (ICU vs. non-ICU) before definitive conclusions can be made.
Within the FOCUS trials, patients with
severe renal dysfunction (CrCL \30 mL/min) were excluded [3, 4] . The CAPTURE registry has provided an opportunity to study a small cohort (26 patients) with renal insufficiency (baseline serum creatinine [1.8 mg/dL) [7] . The majority of patients were male (n = 15, 58%), the mean (SD) age was 67.9 years, and average BMI was 28.2 kg/m 2 [2] . The most prevalent comorbidities among patients with renal impairment and CAP were GERD (n = 8, 31%), history of smoking (n = 7, 27%), and CHF (n = 6, 23%). Most patients (n = 19, 73%) were treated in general practice units. Prior antibiotics were again common; the most frequent antibiotics received prior to ceftaroline were glycopeptides (31%), macrolides (31%), and quinolones (27%).
Concurrent antibiotics were also commonplace (65%). The outcomes among patients with renal insufficiency were generally consistent with the overall cohort.
The overall clinical cure rate was 81% and the mean (standard deviation) LOT was 5.8 (3.1) days. Most patients were sent home (62%) after hospital discharge. These findings add substantially to the literature regarding the effectiveness of ceftaroline in patients with renal dysfunction. However, consistent with the other subgroup analyses, the limited sample size and the potential for selection bias necessitate the need for additional verification prior to routine use in clinical practice.
Another area of interest for clinicians is the ability of ceftaroline to treat MRSA CABP.
Patients with MRSA CABP were specifically excluded from the FOCUS trials due to the inactivity of ceftriaxone against MRSA [2] [3] [4] .
CAPTURE has afforded an opportunity to examine the use of ceftaroline for patients with CABP with positive cultures for MRSA [6] . failure, two patients were transferred to hospice care and one patient had a lobectomy due to a lung abscess. A high proportion of patients were discharged home (46%), while fewer were discharged to another care facility (44%).
Considerations with CAPTURE and Future Directions
Overall, the clinical response rates observed among patients in the CAPTURE registry were consistent with those observed among patients in the FOCUS trials. These findings also highlighted the potential utility of ceftaroline for the treatment of patients with CAP among populations that were excluded from the phase III clinical trials. However, several caveats should be noted when interpreting these findings. First, CAPTURE is a non-comparator, convenience sample, observational registry. As such, all findings need to be interpreted with caution prior to full adoption into clinical practice. This is especially true for patients with CABP due to MRSA. The ability to effectively use ceftaroline for patients with CABP due to MRSA will be better elucidated upon completion of the current ongoing perspective clinical trial that is assessing its efficacy in patients with CABP due to MRSA. Second, it is difficult to fully discern the effectiveness of ceftaroline in CAPTURE as the combination therapy was common and sample size was limited (increasing the potential for type II error) across many specialized population assessed. Third, the role of prescribing bias and confounding on the observed outcomes cannot be elucidated clearly due to the sampling method and non-comparative nature of the registry.
As the data in CAPTURE registry expands, it would be highly beneficial to ascertain ceftaroline's ''real-world'' effectiveness as the number of patients that receive first-line ceftaroline monotherapy across important specialized patient populations increases. It would also be advantageous to include a comparator arm to the registry to measure the effectiveness of ceftaroline relative to other commonly used antibiotic regimens for CAP.
As part of these comparator studies, it is important to compare readmission rates between patients that receive different therapies. This is especially relevant in light of the Patient Protection and Affordable Care Act [25] which will trigger withholding of reimbursement as a penalty for higher-thanexpected readmission rates among Medicaid patients with pneumonia. Finally, it would also be useful to expand the CAPTURE program to examine the effect of ceftaroline use on antibiotic resistance rates within a given institution. Third-generation cephalosporin use within health systems has been linked to increase prevalence of extended spectrum beta-lactamase (ESBL)-producing organisms.
Given the similar spectrum of ceftaroline to ceftriaxone, it would be prudent to evaluate the association of ceftaroline use with prevalence of ESBL-producing organisms.
CONCLUSIONS
Community-acquired bacterial pneumonia continues to be a grave public health concern.
Ceftaroline is a new addition to our antibiotic treatment arsenal for patients with both CAP and CABP. Data from clinical trials suggest that ceftaroline is non-inferior to ceftriaxone and has a reasonable safety profile [2] [3] [4] . These findings have been supported by real-world observational data from CAPTURE [5] [6] [7] [8] [9] [10] . In addition, the CAPTURE program afforded an opportunity to assess the outcomes of patients who were excluded or limited in the original Phase III trials patients in a non-comparative fashion. The CAPTURE registry has provided valuable insights into ceftaroline use in special populations including the elderly, critically ill, those with renal dysfunction, and those with MRSA CABP. As CAPTURE is a retrospective, non-comparator convenience sample registry, all the findings need to be interpreted with caution.
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